Literature DB >> 3632912

Teniposide is not effective in chronic lymphocytic leukemia.

V Zagonel, U Tirelli, A Veronesi, E Galligioni, S Tumolo, M Roncadin, A Carbone, E Grigoletto.   

Abstract

Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3632912     DOI： 10.1007/BF00320143

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


  9 in total

1.  VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).

Authors:  D F Chiuten; J M Bennett; R H Creech; J Glick; G Falkson; H S Brodovsky; C B Begg; F M Muggia; P P Carbone
Journal:  Cancer Treat Rep       Date:  1979-01

2.  Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia.

Authors:  M M Oken; M E Kaplan
Journal:  Cancer Treat Rep       Date:  1979-03

3.  Phase II study of VM 26 in extensively pretreated breast cancer.

Authors:  U Tirelli; G Franchin; D Crivellari; A Veronesi; E Galligioni; M G Trovó; R Talamini; S Tumolo; E Grigoletto
Journal:  Am J Clin Oncol       Date:  1984-10       Impact factor: 2.339

4.  VM26 in malignant hematological diseases. A phase II study.

Authors:  U Tirelli; A Carbone; G Franchin; E Galligioni; A Veronesi; M G Trovo; R Volpe; S Tumolo; E Grigoletto
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Teniposide: a review of 12 years of experience.

Authors:  P J O'Dwyer; M T Alonso; B Leyland-Jones; S Marsoni
Journal:  Cancer Treat Rep       Date:  1984-12

6.  Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).

Authors:  F M Muggia; O S Selawry; H H Hansen
Journal:  Cancer Chemother Rep       Date:  1971-12

7.  A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.

Authors:  U Tirelli; A Carbone; D Crivellari; R Volpe; G Franchin; A Veronesi; E Galligioni; M Trovò; S Tumolo; E Grigoletto
Journal:  Cancer       Date:  1984-08-01       Impact factor: 6.860

8.  Phase II study of teniposide (VM-26) in multiple myeloma.

Authors:  U Tirelli; A Carbone; V Zagonei; F Brema; A Veronesi; E Grigoletto; R Volpe
Journal:  Am J Clin Oncol       Date:  1985-08       Impact factor: 2.339

9.  VM 26 in advanced mycosis fungoides.

Authors:  U Tirelli; A Carbone; S Tumolo; E Galligioni; A Veronesi; M G Trovò; E Grigoletto
Journal:  Tumori       Date:  1981-10-31
  9 in total
  1 in total

Review 1.  Chronic lymphocytic leukaemia: when and how to treat.

Authors:  C Rozman; E Montserrat
Journal:  Blut       Date:  1989-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.